How are energy investors positioned?
Alva Emily Peterson, a director at Amneal Pharmaceuticals, Inc. (NYSE:NASDAQ:AMRX), recently sold 80,000 shares of the company’s Class A common stock. The shares were sold at a weighted average price of $8.90, generating approximately $712,000. The transaction comes as AMRX trades near its 52-week high of $9.47, having delivered an impressive 65% return over the past year. According to InvestingPro analysis, the stock is currently fairly valued. This transaction, dated March 5, 2025, leaves Peterson with 170,771 shares following the sale. The shares were sold in a series of transactions with prices ranging from $8.62 to $9.00 per share. With a market capitalization of $2.76 billion, analysts maintain a positive outlook, setting price targets between $11 and $12. For deeper insights into AMRX’s valuation and comprehensive analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Amneal Pharmaceuticals reported its Q4 2024 earnings, revealing a slight miss on earnings per share (EPS) expectations, with EPS at $0.12 compared to the anticipated $0.15. Despite this, the company’s revenue exceeded forecasts, reaching $731 million against the expected $703.74 million. Amneal has also announced the FDA’s acceptance of their Biologics Licensing Application for two biosimilars of denosumab, in collaboration with mAbxience, with a target action date set for the fourth quarter of 2025. The company aims to expand its presence in the U.S. biosimilars market with these developments. Additionally, Amneal launched a new Parkinson’s drug, Krexant, which has shown promising sales targets. The company has set a revenue guidance range of $3.0 to $3.1 billion for 2025. Furthermore, Amneal’s strategic focus on biosimilars and its collaboration with MedCera in the weight loss and obesity space marks significant steps in its growth strategy. Lastly, Amneal received credit upgrades from S&P and Moody’s, reflecting improved financial performance and debt reduction efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.